Prudential Financial’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-10,875
| Closed | -$37K | – | 2496 |
|
|
2018
Q3 | $37K | Buy |
10,875
+260
| +2% | +$937 | ﹤0.01% | 2406 |
|
|
2018
Q2 | $40K | Buy |
10,615
+230
| +2% | +$1.12K | ﹤0.01% | 2410 |
|
|
2018
Q1 | $42K | Hold |
10,385
| – | – | ﹤0.01% | 2325 |
|
|
2017
Q4 | $48K | Hold |
10,385
| – | – | ﹤0.01% | 2312 |
|
|
2017
Q3 | $74K | Buy |
10,385
+290
| +3% | +$2.08K | ﹤0.01% | 2309 |
|
|
2017
Q2 | $73K | Hold |
10,095
| – | – | ﹤0.01% | 2313 |
|
|
2017
Q1 | $62K | Hold |
10,095
| – | – | ﹤0.01% | 2308 |
|
|
2016
Q4 | $59K | Hold |
10,095
| – | – | ﹤0.01% | 2315 |
|
|
2016
Q3 | $54K | Buy |
+10,095
| New | +$54.4K | ﹤0.01% | 2298 |
|
|
2016
Q2 | – | Sell |
-10,635
| Closed | -$50K | – | 2360 |
|
|
2016
Q1 | $50K | Hold |
10,635
| – | – | ﹤0.01% | 2269 |
|
|
2015
Q4 | $54K | Sell |
10,635
-100
| -0.9% | -$475 | ﹤0.01% | 2207 |
|
|
2015
Q3 | $38K | Buy |
10,735
+200
| +2% | +$1.34K | ﹤0.01% | 2199 |
|
|
2015
Q2 | $105K | Sell |
10,535
-100
| -0.9% | -$1.07K | ﹤0.01% | 2186 |
|
|
2015
Q1 | $135K | Buy |
10,635
+500
| +5% | +$6.43K | ﹤0.01% | 2170 |
|
|
2014
Q4 | $143K | Hold |
10,135
| – | – | ﹤0.01% | 2132 |
|
|
2014
Q3 | $139K | Sell |
10,135
-8,864
| -47% | -$136K | ﹤0.01% | 2154 |
|
|
2014
Q2 | $292K | Buy |
+18,999
| New | +$269K | ﹤0.01% | 2189 |
|
Prudential Financial's KERX Position: Q4 2018 in Review
Prudential Financial sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 10,875 shares — an estimated $37K sold.
Prudential Financial first reported a position in KERX in Q2 2014 and held it in 17 quarters. The position peaked at $292K in Q2 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Prudential Financial reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Prudential Financial sold 10,875 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $37K.
- Prudential Financial first reported a position in Keryx Biopharmaceuticals Inc in Q2 2014 and held it in 17 quarters.
- Prudential Financial's Keryx Biopharmaceuticals Inc position peaked at $292K in Q2 2014.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Prudential Financial's 13F filing for Q4 2018, filed 7 Feb 2019.